Abstract:Malignancy is defined by a set of abnormal biological capacities, termed the hallmarks of cancer. Decades of histopathologic assessment and molecular profiling of human tumors have demonstrated there are multiple ways cells can acquire each hallmark. As a result, tumors with the same clinical characteristics can vary dramatically across individuals and these distinct molecular vulnerabilities can have important prognostic and therapeutic implications. It is unclear when these differences originate. Oncogenic aberrations are acquired within the context of germline genomes which differ across individuals at millions of polymorphic sites, but the role of germline variants in somatic evolution remains poorly understood. The most compelling example is that deleterious germline variants in BRCA1 and, to a lesser extent, BRCA2 are preferentially associated with the development of TNBC, implying germline variants sculpt specific subtypes of disease. The mechanistic basis for this preference is incompletely characterized. Additionally, germline variants that upregulate the mTOR pathway are associated with further deregulation of mTOR via somatic PTEN loss-of-function. Moreover, pathogenic germline variants in cancer predisposition genes promote somatic bi-allelic inactivation in a lineage-dependent manner and rare variants across a diverse list of genes can modulate somatic mutational processes. In prostate cancer, germline variants can modulate genomic stability, tumor-specific DNA methylation and gene regulation at the transcriptional and translational levels. Pathogenic germline variants in genes related to telomere and mitotic function increase the risk of sarcoma. Differences in breast cancer subtype frequencies across ancestral populations further suggest germline contributions. These data point to an underappreciated role of the germline genome in somatic tumor evolution. Various lines of evidence suggest that avoidance of the adaptive immune system is another strong determinant of which somatic mutations persist within a tumor. It remains less clear how germline differences influence immunoediting. Levels of interferon signaling and cytotoxic T-cell infiltration are estimated to be 15-20% heritable. Generally, germline variants have not been considered a good source of immunogenic epitopes as cytotoxic response should be dampened by central tolerance. However, non-mutated immunogenic epitopes have been identified in genes such as ERBB2 in breast and ovarian cancer and H4 histone in prostate cancer, amongst others. Antigens with weak binding affinity for MHC receptors can escape central tolerance and elicit an immune response. Tissue-restricted post-translational modifications can also circumvent central tolerance. Peripheral self-reactive T cells are present at similar frequencies to T cells specific to foreign antigens but are held in an anergic state by regulatory T cells (Treg). However, Treg depletion in healthy mouse models led to the natural occurrence of self-reactive CD4+ T cells. Further, there is mounting evidence for innate-like T-cell populations within mouse and tumor malignancies that have increased propensity for self-reactivity. Altogether, these data suggest that under specific circumstances and disruptions to immune homeostasis, a subset of T-cells may respond to germline-derived epitopes during tumorigenesis. Building on these observations, we sought to investigate whether germline variants sculpt somatic evolution by mediating immunoediting. Specifically, we hypothesize that the burden of germline-derived epitopes in recurrently amplified driver genes may select against gene amplification. This is because amplification of a gene with a high burden of germline-derived epitopes would increase epitope availability, likelihood of epitope presentation and immune-mediated cell death. Instead, immune pressures may select for amplification of an alternate driver gene with a lower germline-mediated epitope burden. Motivation for this hypothesis draws upon insights from the immuno-oncology and population genetics fields. First, in a subset of tumors, somatic tumor mutational burden (TMB), specifically clonal TMB, is positively associated with immunotherapy response. Second, recent successes with cancer vaccines developed from non-somatically mutated, tumor-specific overexpressed peptides, i.e. HER2, TERT and WT1, suggests germline epitopes contribute to immune response. Finally, genome-wide association studies have demonstrated the power of aggregating germline-variants with weak effects into a unified risk score, i.e. polygenic risk score (PRS). Thus, we hypothesized aggregating germline-derived epitopes, with weak individual effects, akin to PRS, may provide a powerful metric to assess germline-mediated immunoediting. We addressed this question in breast cancer for three reasons. First, the well-characterized link be -Abstract Truncated-

Effective immunosurveillance of clonally expanded mammary aneuploid cells

Isogenic Cell Lines Derived from Specific Organ Metastases Exhibit Divergent Cytogenomic Aberrations

Immune-driven clonal cell selection at the intersection among cancer, infectious diseases, autoimmune disorders, and senescence

The hallmarks of cancer immune evasion

Abstract NG01: Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity

Converging and evolving immuno-genomic routes toward immune escape in breast cancer

Abstract 3931: Breast cancer genomic architecture contributes to immune escape across metastasis

An aneuploidy epistasis map reveals metabolic vulnerabilities associated with supernumerary chromosomes in cancer

Non-cell-autonomous cancer progression from chromosomal instability

Abstract B032: Comprehensive analysis of clonality, segregation errors, chromosomal instability and heterogeneity in cancer cell lines and cancer samples reveals that cancer evolution is often promoted by highly aberrant cellular divisions

Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity

Abstract 6630: Non-cell-autonomous cancer progression from chromosomal instability

An evolving cancer instigates clonally unrelated neighboring cells to form distant metastases

Premalignancy induced B cell-centered immune aggregates for immune-prevention against triple negative breast cancer

Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells

A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction

Abstract A15: Immune-related Changes in Breast Cancer Tumor Evolution

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling

Chromosomal instability can favor macrophage-mediated immune response and induce a broad, vaccination-like anti-tumor IgG response

Breast tumours maintain a reservoir of subclonal diversity during expansion